Ponesimod shows 5-year safety and lasting MS benefits

Credibility

Interest

Key Takeaway

Over five years, the drug ponesimod stayed safe for most people and continued to reduce relapses and signs of disease activity in relapsing multiple sclerosis (RMS).

What They Found

Researchers followed people with relapsing MS for up to five years to see how well ponesimod worked and how safe it was. Most patients (about 94%) had at least one side effect during the study, but serious side effects were uncommon (about 13%) and only about 9% stopped treatment because of side effects. People who took ponesimod the whole time had fewer yearly relapses on average than those who switched from another drug (0.143 vs 0.184 relapses per year). Fewer people on continuous ponesimod had any return of disease activity by the end of the study — a measure called NEDA‑3 (17.5% stayed free of relapses, disability worsening, and new MRI lesions vs 7.5% who switched). Overall, no new safety problems showed up over the long term, and the benefit in controlling MS signs seen earlier in the study continued over the five years.

Who Should Care and Why

People with relapsing MS should care because this study suggests ponesimod can keep helping to lower relapse risk and disease activity over many years — like finding a car that keeps running well after long use. Caregivers may find reassurance knowing most people did not have serious problems and only a small number had to stop treatment because of side effects. Neurologists and other healthcare providers can use this information when discussing long-term treatment plans and monitoring needs with patients. Those thinking about switching treatments might note that staying on ponesimod from the start showed better control than switching onto it later in this study. For daily life, better long-term control can mean fewer flare-ups, fewer new MRI changes, and possibly less chance of disability getting worse, which can help with planning work, family, and care needs.

Important Considerations

The study did not include people who never entered the long-term part, so results mostly reflect those who stayed in the study and may have tolerated treatment well. About 94% had at least one side effect, so while serious problems were uncommon, side effects are still common and should be discussed with your doctor. This study compared people who stayed on ponesimod with those who switched from another specific drug, so results might not apply the same way if switching from other MS treatments.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Treatment Updates Clinical Trials MS Progression

Article Topics:

Long-term extension studyPonesimodRelapsing multiple sclerosisTeriflunomide

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News